BIIB

Biogen Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$250.48

Price (1 Year)

$253.62 $164.42

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %28.3 / %30
Non-compliant assets / Total market cap %2.3 / %30
Non-compliant revenue / Total income %0.9 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.

Website

Analysis (Turkish): BIIB Hissesi Caiz mi, Helal mi? Biogen Inc. Katılım Analizi